Canché AA, Salcido PP, Cedillo FM, Aisa ÁA, Amezcua MA, Rojas SM, Espinosa AS, Espinosa DS, Reza OM, Rodríguez WF, Díaz GE

Language: Spanish
References: 28
Page: 171-176
PDF size: 283.96 Kb.

ABSTRACT

Idiopathic thrombocytopenic purpura (ITP) is a clinical syndrome characterized mainly by widespread petechiae with a high rate of bleeding associated with antibody-mediated platelet destruction (peripheral blood platelets less than 100X109 /L).Has an incidence of 1.6 to 3.9 cases per 100,000 people per year. Its diagnosis is made by exclusion, ruling out other causes of thrombocytopenia. The primary goal of treatment is to prevent bleeding by controlling the number of platelets. It is recommended to treat patients with bleeding and figures below 30 000 platelets /mcL. The duration of treatment should be until there is an increase in the platelet number.The initial treatment should be steroids (prednisone, dexamethasone or methylprednisolone).You need to add another treatment in patients with severe thrombocytopenia, platelet counts with less than‹10000/mcL, and when symptomatic despite treatment by two or three weeks with glucocorticoids. In patients refractory to steroids may be used other drugs. Cyclosporine has a platelet response up to 44 to 75% of patients. Of erythropoietin receptor agonists, romiplostim has shown promising results, as it increases the platelet, with fewer adverse effects and less need for splenectomy. Cyclophosphamide with complete response is only obtained in 10-20% of patients with chronic ITP and 40% of them achieved partial remission. Vinca alkaloids (vincristine and vinblastine), danazol, and splenectomy are other options.

REFERENCES

1. Neunert C. Idiopathic thrombocytopenic purpura: advances in management. Clin Adv Hematol Oncol 2011;9(5):404-406.

2. Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol 2011;153(4):437-50. Epub 2011 Apr 5.

3. Pustovaia EI, Safonova TI, Riadnenko AA, Kolosova EN. Clinical statistics and effectiveness of different treatments of idiopathic thrombocytopenic purpura. TerArkh.

4. Rodeghiero F, et al. Standardization of terminology, definition and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386-2393.

5. Provan D, et al. International consensus reports on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168-186.

6. Cuker A, et al. Immune thrombocytopenia. American Society of Hematology 2010;377-384.

7. George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica 2009;94(6): 759-762.

8. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168.

9. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386.

10. Guidry JA, George JN, Vesely SK, et al. Corticosteroid sideeffects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol 2009;83:175.

11. Praituan W, Rojnuckarin P. Faster platelet recovery by highdose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. J ThrombHaemost 2009;7:1036.

12. Donald M. Arnold, Ishac Nazi, et al. Combination immunosuppressant therapy for patients with chronicrefractory immune thrombocytopenic purpura. Blood 2010;115:29-31.

13. Stevens W, Koene H, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. The Netherlands Journal of Medicine 2006;356-363.

14. Kuter DJ, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610):395-403.

15. Kuter DJ, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. New Engl J Med 2011; 363(20).

16. Bussel JB, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357(22): 2237-2247.

17. Liberman AC, Druker J, Refojo D, y col. Mecanismos moleculares de acción de algunas drogas inmunosupresoras. Medicina 2008;68:455-464.

18. Díaz GC. Mecanismos de acción de los fármacos inmunosupresores. Revista Chilena de Reumatología 2008; 24(2):73-88.

19. Vizcaíno G, Diez-Ewald M, Vizcaíno-Carruyo J. Tratamiento de la púrpura trombocitopénica inmunitaria crónica. Buscando algo mejor. Invest Clin 2009;50(1):95-108.

20. Facon T, Caulier MT, Wattel E, et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol 1994;86:678.

21. Shvidel L, Sigler E, Shtalrid M, Berrebi A. Vincristine-loaded platelet infusion for treatment of refractory autoimmune hemolytic anemia and chronic immune thrombocytopenia: rethinking old cures. Am J Hematol 2006; 81:423.

22. Vizcaíno G, Diez-Ewald M, y col. Tratamiento de la púrpura trombocitopénica inmunitaria crónica. Buscando algo mejor. Instituto de Investigaciones Clínicas Dr. Américo Negrette.

23. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350(4):351-360.

24. Waintraub SE, Brody JI. Use of anti-D in immune thrombocytopenic purpura as a means to prevent splenectomy: case reports from two University Hospital Medical Centers. Semin Hematol 2000;37:45-49.

25. Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase iii multicenter randomized trial. Cancer 2006;106(4):848-58. [PubMed 16404741]

26. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004;79:504.

27. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.

28. Weinblatt ME, Kochen J, Ortega J. Danazol for Children with Immune Thrombocytopenic Purpura. Am J Dis Child 1988;142(12):1317-1319.